Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

754.93
-7.8850-1.03%
Volume:132.83K
Turnover:99.88M
Market Cap:77.72B
PE:18.67
High:765.60
Open:763.15
Low:743.57
Close:762.81
52wk High:859.34
52wk Low:553.87
Shares:102.95M
Float Shares:98.88M
Volume Ratio:1.33
T/O Rate:0.13%
Dividend:3.64
Dividend Rate:0.48%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.45
PE(LYR):18.20

Loading ...

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
17 hours ago

Sector Update: Healthcare Stocks Rise Late Afternoon

MT Newswires Live
·
18 hours ago

Regeneron Says Pasatru Showed Sustained Benefit in OPTIMA Trial Extension for Genetic Disorder

MT Newswires Live
·
21 hours ago

Regeneron announces results from Phase 3 OPTIMA trial of Pasatru

TIPRANKS
·
22 hours ago

Regeneron Says Phase 3 Optima Extension Shows Zero New HO Lesions with Pasatru in Adult FOP Patients Through Week 84

Reuters
·
22 hours ago

Regeneron Pharmaceuticals - Pasatru Shows Sustained Efficacy and Consistent Safety Profile from Weeks 56 to 84

THOMSON REUTERS
·
22 hours ago

Regeneron Pharmaceuticals - Pasatru Maintains Well-Tolerated Safety Profile Through Week 84

THOMSON REUTERS
·
22 hours ago

Bank of America Securities Sticks to Their Buy Rating for Regeneron (REGN)

TIPRANKS
·
Yesterday

Regeneron Pharmaceuticals, Inc. : Bofa Global Research Raises Price Objective to $908 from $891

THOMSON REUTERS
·
Yesterday

Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative

Simply Wall St.
·
Oct 11

Regeneron Pharma Price Target Raised to $779.00/Share from $758.00 by Morgan Stanley

Dow Jones
·
Oct 07

Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $779 From $758

MT Newswires Live
·
Oct 07

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
Oct 07

Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment to License and Collaboration Agreement - SEC Filing

THOMSON REUTERS
·
Oct 06

Regeneron Pharmaceuticals - Ipr&D Charge Expected to Reduce Q3 2026 Gaap and Non-Gaap EPS by $0.18 - SEC Filing

THOMSON REUTERS
·
Oct 06

Regeneron to Present Phase 3 C-POST Overall Survival Update for Adjuvant Libtayo in High-Risk CSCC at ESMO 2026

Reuters
·
Oct 06

JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $950 From $900, Keeps Overweight Rating

MT Newswires Live
·
Oct 06

Sanofi Can Move Forward to Pursue Deals

Dow Jones
·
Oct 06

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

Regeneron Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Oct 06